Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer.
Metastasis-directed external beam radiation therapy (EBRT) delivered for limited-volume disease, integrated with systemic radioligand therapy, may improve long-term disease control across the spectrum of metastatic prostate cancer. We examined 88 patients with metastatic prostate cancer who received both lutetium-177 P...